257 247

Cited 2 times in

Synergic Effect of Metformin and Everolimus on Mitochondrial Dynamics of Renal Cell Carcinoma

DC Field Value Language
dc.contributor.author이광석-
dc.contributor.author한웅규-
dc.date.accessioned2022-12-22T02:44:07Z-
dc.date.available2022-12-22T02:44:07Z-
dc.date.issued2022-07-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/191669-
dc.description.abstractRenal cell carcinoma (RCC) frequently recurs or metastasizes after surgical resection. Everolimus, an mTOR inhibitor, is used as a second-line treatment, but the response of RCC to everolimus is insufficient. Metformin is an antidiabetic drug; recent reports have indicated its anti-cancer effects in various cancers, and it is known to have synergistic effects with other drugs. We investigated the possibility of coadministering everolimus and metformin as an effective treatment for RCC. RCC cells treated with a combination of the two drugs showed significantly inhibited cell viability, cell migration, and invasion, and increased apoptosis compared to those treated with each drug alone. An anti-cancer synergistic effect was also confirmed in the xenograft model. Transcriptome analysis for identifying the underlying mechanism of the combined treatment showed the downregulation of mitochondrial fusion genes and upregulation of mitochondrial fission genes by the combination treatment. Changes in mitochondrial dynamics following the combination treatment were observed using LysoTracker, LysoSensor, and JC-1 staining. In conclusion, the combination of everolimus and metformin inhibited RCC growth by disrupting mitochondrial dynamics. Therefore, we suggest that a treatment combining metformin and everolimus disrupts mitochondrial dynamics in RCC, and may be a novel strategy for RCC treatment.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherMDPI-
dc.relation.isPartOfGENES-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHCarcinoma, Renal Cell* / drug therapy-
dc.subject.MESHCarcinoma, Renal Cell* / genetics-
dc.subject.MESHCarcinoma, Renal Cell* / pathology-
dc.subject.MESHCell Line, Tumor-
dc.subject.MESHCell Proliferation-
dc.subject.MESHEverolimus / pharmacology-
dc.subject.MESHEverolimus / therapeutic use-
dc.subject.MESHHumans-
dc.subject.MESHKidney Neoplasms* / drug therapy-
dc.subject.MESHKidney Neoplasms* / genetics-
dc.subject.MESHKidney Neoplasms* / pathology-
dc.subject.MESHMetformin* / pharmacology-
dc.subject.MESHMitochondrial Dynamics-
dc.subject.MESHNeoplasm Recurrence, Local-
dc.titleSynergic Effect of Metformin and Everolimus on Mitochondrial Dynamics of Renal Cell Carcinoma-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Urology (비뇨의학교실)-
dc.contributor.googleauthorSeong-Hwi Hong-
dc.contributor.googleauthorKwang-Suk Lee-
dc.contributor.googleauthorHyun-Ji Hwang-
dc.contributor.googleauthorSung-Yul Park-
dc.contributor.googleauthorWoong-Kyu Han-
dc.contributor.googleauthorYoung-Eun Yoon-
dc.identifier.doi10.3390/genes13071211-
dc.contributor.localIdA02668-
dc.contributor.localIdA04308-
dc.relation.journalcodeJ03926-
dc.identifier.eissn2073-4425-
dc.identifier.pmid35885994-
dc.subject.keywordeverolimus-
dc.subject.keywordmetformin-
dc.subject.keywordmitochondrial dynamics-
dc.subject.keywordrenal cell carcinoma-
dc.contributor.alternativeNameLee, Kwang Suk-
dc.contributor.affiliatedAuthor이광석-
dc.contributor.affiliatedAuthor한웅규-
dc.citation.volume13-
dc.citation.number7-
dc.citation.startPage1211-
dc.identifier.bibliographicCitationGENES, Vol.13(7) : 1211, 2022-07-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.